The introduction of oral direct‐acting antivirals (DAAs) has dramatically changed the landscape of HCV treatment. However, a small percentage of patients fail to achieve sustained virologic response (SVR). Understanding the number of people who fail on DAAs and require re‐treatment is important for budget impact and disease burden projections. To quantify the number of HCV patients who fail to achieve SVR on oral DAAs (NS5A vs. non‐NS5A) and require re‐treatment.